Bontril Slow-Release

Bontril Slow-Release Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Bontril Slow-Release is a brand name. Its generic name is Phendimetrazine.

Introduction

Bontril Slow-Release is a sympathomimetic amine. It was originally approved by the Food and Drug Administration (FDA) as an appetite suppressant for the short-term treatment of obesity.

Uses

Bontril Slow-Release is used in the short-term management of exogenous obesity. It is used in combination with an individually tailored diet plan as part of a total weight-loss program.

Mechanism of Action

Bontril Slow-Release works by increasing certain neurotransmitters and hormones, including dopamine, epinephrine, and norepinephrine. This stimulates the hypothalamus, impacts hunger signals, and help to reduce appetite and calorie intake.

How Long Does It Take to Work?

The effects of Bontril Slow-Release should be noticed within an hour of taking the medication. The maximum effect can be felt about three hours after taking the medication.

Absorption

Bontril Slow-Release is rapidly absorbed from the gastrointestinal tract after oral administration. The peak plasma concentration may vary from about 0.2 to 1.4 mcg/ml.

Route of Elimination

Bontril Slow-Release is metabolized primarily by the liver. The metabolites are excreted in the urine and some are excreted in the feces.

Dosage

Bontril Slow-Release is available in a variety of dosage forms (e.g., tablets, capsules, and other solid dosage forms). The recommended dose for adults is 35 mg and 105 mg daily taken in 1–3 divided doses 30 minutes before meals. The daily dose should not exceed 105 mg.

Administration

Bontril Slow-Release should be administered orally, either dissolved in water or taken with food. Do not crush or chew the tablets.

Side Effects

Common side effects of Bontril Slow-Release include dry mouth, insomnia, nervousness, restlessness, blurred vision, dizziness, constipation, nausea, vomiting, and headaches.

Toxicity

Bontril Slow-Release has a low potential for toxicity. Overdose can be fatal, and symptoms may include convulsions, loss of consciousness, and coma.

Precautions

Phenemtrazine should not be used in pregnant or nursing women. Those with a history of substance abuse or cardiovascular disease should also avoid using this medication.

Interactions

Phenemtrazine may interact with other medications, including sedatives, monoamine oxidase inhibitors, tricyclic antidepressants, and opioid analgesics.

Disease Interaction

Patients with a history of hyperthyroidism, hypertension, diabetes, or glaucoma should not take this medication. It should also be used with caution in those with a history of drug dependence or alcohol abuse.

Drug Interaction

Phenemtrazine may interact with other drugs, including opioid analgesics, tricyclic antidepressants, monoamine oxidase inhibitors, and sedatives.

Food Interactions

Bontril Slow-Release should not be taken with alcohol or any other medication. Food should be consumed at least an hour after taking the medication in order to maximize results.

Pregnancy Use

Bontril Slow-Release should be avoided in pregnant women.

Lactation Use

Bontril Slow-Release should not be used by nursing mothers.

Acute Overdose

Acute overdoses of Bontril Slow-Release can be fatal. Symptoms of acute overdose include convulsions, loss of consciousness, and coma.

Contraindication

Bontril Slow-Release is contraindicated in pregnant and nursing women. It is also contraindicated in individuals with drug dependence or alcohol abuse.

Use Direction

Bontril Slow-Release should be taken according to doctor’s instructions. Do not crush or chew the tablets.

Storage Condition

Tablets should be stored at room temperature, out of reach of children.

Volume of Distribution

Bontril Slow-Release is highly bound to plasma proteins.

Half-Life

The half-life of Bontril Slow-Release is approximately one to four hours.

Clearance

The clearance of Bontril Slow-Release is approximately 25 to 30 mL/min.

Here you find in details version of Bontril Slow-Release

Some Frequently Asked Questions About Bontril Slow-Release

https://www.medicinesfaq.com/brand/bontril-slow-release, http://classyfire.wishartlab.com/tax_nodes/C0000000, http://classyfire.wishartlab.com/tax_nodes/C0000002, http://classyfire.wishartlab.com/tax_nodes/C0000107, http://classyfire.wishartlab.com/tax_nodes/C0000392, http://classyfire.wishartlab.com/tax_nodes/C0000370, http://classyfire.wishartlab.com/tax_nodes/C0003899, http://classyfire.wishartlab.com/tax_nodes/C0002279, http://classyfire.wishartlab.com/tax_nodes/C0002239, http://classyfire.wishartlab.com/tax_nodes/C0004140, http://classyfire.wishartlab.com/tax_nodes/C0001167, http://classyfire.wishartlab.com/tax_nodes/C0004139, http://classyfire.wishartlab.com/tax_nodes/C0004557, http://classyfire.wishartlab.com/tax_nodes/C0004150, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8059, http://www.genome.jp/dbget-bin/www_bget?drug:D08347, http://www.genome.jp/dbget-bin/www_bget?cpd:C07904, https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=30487, https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506122, https://www.chemspider.com/Chemical-Structure.28295.html, https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=33272, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=8059, https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1615439, https://zinc.docking.org/substances/ZINC000022010387, http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000574, http://www.pharmgkb.org/drug/PA450902, http://www.rxlist.com/cgi/generic/phendime.htm, https://www.drugs.com/phendimetrazine.html, https://en.wikipedia.org/wiki/Phendimetrazine,